Abstract
The microtubule (MT) represents a highly validated target for therapy. Insights into the complex nature of the dynamic microtubule physiology will provide the basis for developing novel microtubule targeting agents with enhanced efficacy and minimised toxicity. In this article, with an emphasis on translational applications, we have summarised relevant aspects of tubulin physiology in the context of developing MT binding agents as therapeutic agents. Case studies were included to illustrate therapeutic developments in prostate cancer and current strategies to discover novel agents or targets for therapy.
Keywords: Microtubule (MT), microtubule associated proteins (MAPs), microtubule targeting agents (MTAs), chemotherapy, tubulin heterodimers, polymerases, angiogenesis, neutropenia, p21-activated kinase 6 (PAK6), prostate cancer
Current Pharmaceutical Design
Title:Approaches for Developing Novel Microtubule Targeting Agents (MTAs) for Therapeutic Exploitation
Volume: 18 Issue: 19
Author(s): Aswini Krishnan, James Wilson and Hing Y. Leung
Affiliation:
Keywords: Microtubule (MT), microtubule associated proteins (MAPs), microtubule targeting agents (MTAs), chemotherapy, tubulin heterodimers, polymerases, angiogenesis, neutropenia, p21-activated kinase 6 (PAK6), prostate cancer
Abstract: The microtubule (MT) represents a highly validated target for therapy. Insights into the complex nature of the dynamic microtubule physiology will provide the basis for developing novel microtubule targeting agents with enhanced efficacy and minimised toxicity. In this article, with an emphasis on translational applications, we have summarised relevant aspects of tubulin physiology in the context of developing MT binding agents as therapeutic agents. Case studies were included to illustrate therapeutic developments in prostate cancer and current strategies to discover novel agents or targets for therapy.
Export Options
About this article
Cite this article as:
Krishnan Aswini, Wilson James and Y. Leung Hing, Approaches for Developing Novel Microtubule Targeting Agents (MTAs) for Therapeutic Exploitation, Current Pharmaceutical Design 2012; 18 (19) . https://dx.doi.org/10.2174/138161212800626111
DOI https://dx.doi.org/10.2174/138161212800626111 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Human Pseudoautosomal Region (PAR): Origin, Function and Future
Current Genomics Multi-Component Reactions Using Indium(III) Salts
Current Organic Chemistry Regulation of T cell Apoptosis during the Immune Response
Current Molecular Medicine “Letting the Air In” Can Set the Stage for Tumor Recurrences
Current Cancer Therapy Reviews Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance
Current Medicinal Chemistry Anti-Angiogenic Peptides for Cancer Therapeutics
Current Pharmaceutical Biotechnology Targeting STAT1 in Both Cancer and Insulin Resistance Diseases
Current Protein & Peptide Science Tumor Necrosis Factor: How to Make a Killer Molecule Tumor-Specific?
Current Cancer Drug Targets Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) Intraoperative Targeted Optical Imaging: A Guide towards Tumor-Free Margins in Cancer Surgery
Current Pharmaceutical Biotechnology Pharmacological Implications of MMP-9 Inhibition by ACE Inhibitors
Current Medicinal Chemistry Overview of Medicinally Important Diterpenoids Derived from Plastids
Mini-Reviews in Medicinal Chemistry Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging
Mini-Reviews in Medicinal Chemistry Mouse Models of Primary Sjogren’s Syndrome
Current Pharmaceutical Design Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System
Current Cancer Drug Targets Cancer Stem Cells: How can we Target them?
Current Medicinal Chemistry Cytoplasmic CXCR4 High-Expression Exhibits Distinct Poor Clinicopathological Characteristics and Predicts Poor Prognosis in Triple-Negative Breast Cancer
Current Molecular Medicine Cardiac Toxicities of Antiangiogenic Therapies
Current Angiogenesis (Discontinued) An Analysis of Structure-function Co-relation between GLI Oncoprotein and HLA Immune-gene Transcriptional Regulation through Molecular Docking
Current Cancer Therapy Reviews The Application of Photofrin II® as a Sensitizing Agent for Ionizing Radiation-A New Approach in Tumor Therapy?
Current Medicinal Chemistry